Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy
Go back to Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy| Capricor Therapeutics, Inc. (NASDAQ: CAPR) | Delayed: 25.80 +0.76 (3.04%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.04 | 52 Week High | $5.40 | |||
| Open | $25.11 | 52 Week Low | $1.88 | |||
| Day High | $26.12 | P/E | N/A | |||
| Day Low | $25.00 | EPS | $0.00 | |||
| Volume | 773,706 | |||||
